ReviewThyroid : official journal of the American Thyroid Association2019
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.
Review in Thyroid : official journal of the American Thyroid Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 1 synthesis or guideline pooled it, 258 citations in OpenAlex.
- Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2023Trial
- Pharmacological treatment of MASH.Diabetologia · 2026Review
- Pharmacological Potential of Selenoproteins in the Regulation of Oxidative Stress in Liver Diseases.Pharmaceutics · 2026Review
- MASLD as Complication of Diabetes.Diabetes · 2026Review
- Article
- A case of thyroid hormone resistance with coincidental pituitary macroadenoma.JCEM case reports · 2026Article
- Paeoniflorin Modulates TREM-1/NF-κB/LXRα/ABCG1 Pathway to Improve Cholesterol Metabolism and Inflammation in Hyperlipidemic Rat.International journal of molecular sciences · 2026Article
- The relationship between metabolic associated fatty liver disease and thyroid nodule: a cross-sectional study in China.BMC gastroenterology · 2026Observational
- FT3 Levels and Systemic Inflammation: Evidence From a Population-Based NHANES Analysis.Mediators of inflammation · 2026Article
- Development and validation of a novel analytical method for related substances of resmetirom and identification of new degradation products.Frontiers in chemistry · 2026Article
- Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE-/- mice.PloS one · 2026Article
- Exploring the link between metabolic dysfunction-associated fatty liver disease and subclinical hypothyroidism in adolescents: a comprehensive review.Frontiers in pediatrics · 2026Review
- The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Frontiers in medicine · 2026Review
- Review
- Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials.Archives of pharmacal research · 2025Review
- Novel Aurone Derivative Ameliorates MASH Lipid Metabolism via the AMPK-ACC-PPARα Axis.International journal of molecular sciences · 2025Article
- Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine.Clinical drug investigation · 2025Review
- Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.Life (Basel, Switzerland) · 2025Review
- Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration.Clinical epigenetics · 2025Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 4 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.